volume 9, issue 1, P256-285 2017
DOI: 10.18632/aging.101158
View full text
Sifat Maria, Mark H. Swanson, Larry T. Enderby, Frank D’Amico, Brianna Enderby, Rebekah M. Samsonraj, Amel Dudakovic, Andre J. van Wijnen, Paula A. Witt-Enderby

Abstract: This one-year double blind randomized control trial assessed the effects of nightly melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7; MSDK) on bone mineral density (BMD) and quality of life (QOL) in postmenopausal osteopenic women (ages 49-75). Compared to placebo, MSDK treatment increased BMD in lumbar spine (4.3%) and left femoral neck (2.2%), with an upward trend for total left hip (p=0.069). MSDK increased serum P1NP levels and reduced bone turnover (CTx:P1NP). Psychometric analyses indicated…

expand abstract